Avelas Biosciences Presents Phase II, Period 1 Data in Poster Session at San Antonio Breast Cancer Symposium
SAN DIEGO, December 4, 2018 – Avelas Biosciences, Inc., a clinical-stage oncology company developing AVB-620 for real-time cancer detection, presented the initial results of the first part of its Phase II clinical trial in a poster session at this week’s San Antonio Breast Cancer Symposium (SABCS). The poster, titled “Use of a fluorescent activatable cell penetrating peptide imaging agent (AVB-620) to identify positive and close margins intraoperatively,” is available at the conference’s poster session and online after the conference.
“Our Phase II, Period 1 data demonstrate the promise of utilizing AVB-620 during surgery to solve a significant unmet medical need for women with breast cancer,” said Steven Chen, MD, Avelas’ Chief Medical Officer. “AVB-620 has shown its potential for identifying malignant tissue and lymph nodes intraoperatively and has the potential to be a useful adjunct to current surgical techniques to decrease positive margin rates and subsequent re-excisions. We look forward to observing AVB-620 in the prospective second period of this trial.”
In Phase II, Period 1, 32 patients were dosed at a number of prominent cancer centers across the United States. No adverse events attributable to AVB-620 were observed. The trial results reported that:
- 35% of patients had at least one positive margin confirmed by pathology (invasive tumor on ink or DCIS < 2mm from surface, or positive shave margin)
- 62% of patients had at least one close or positive margin confirmed by pathology (invasive tumor < 2mm or DCIS < 2mm from surface or a positive shave margin)
- 84% of patients with positive/close margins were identified using fluorescent imaging
- 80% of positive node patients (n=5) were identified utilizing fluorescent imaging
For more information, please visit the SABCS website: https://www.sabcs.org/.
About Avelas Biosciences
Avelas Biosciences is a San Diego-based drug-device company focused on developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 improves surgery by detecting cancer in real-time and has the potential to become part of standard-of-care treatment for a variety of cancer surgeries. AVB-620 has completed a Phase Ib clinical trial assessing safety, pharmacokinetics, and fluorescence properties using tissue image analysis. A Phase II clinical trial for AVB-620 in breast cancer is ongoing. Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry.